Evoke Pharma EBITDA 2012-2024 | EVOK
Evoke Pharma ebitda from 2012 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Evoke Pharma Annual EBITDA
(Millions of US $) |
| 2023 |
$-7 |
| 2022 |
$-8 |
| 2021 |
$-8 |
| 2020 |
$-13 |
| 2019 |
$-7 |
| 2018 |
$-8 |
| 2017 |
$-11 |
| 2016 |
$-11 |
| 2015 |
$-12 |
| 2014 |
$-13 |
| 2013 |
$-3 |
| 2012 |
$-2 |
| 2011 |
$-2 |
Evoke Pharma Quarterly EBITDA
(Millions of US $) |
| 2024-09-30 |
$-1 |
| 2024-06-30 |
$-1 |
| 2024-03-31 |
$-2 |
| 2023-12-31 |
$-2 |
| 2023-09-30 |
$-2 |
| 2023-06-30 |
$-2 |
| 2023-03-31 |
$-2 |
| 2022-12-31 |
$-2 |
| 2022-09-30 |
$-2 |
| 2022-06-30 |
$-2 |
| 2022-03-31 |
$-2 |
| 2021-12-31 |
$-2 |
| 2021-09-30 |
$-2 |
| 2021-06-30 |
$-2 |
| 2021-03-31 |
$-3 |
| 2020-12-31 |
$-2 |
| 2020-09-30 |
$-2 |
| 2020-06-30 |
$-7 |
| 2020-03-31 |
$-2 |
| 2019-12-31 |
$-1 |
| 2019-09-30 |
$-2 |
| 2019-06-30 |
$-2 |
| 2019-03-31 |
$-2 |
| 2018-12-31 |
$-2 |
| 2018-09-30 |
$-2 |
| 2018-06-30 |
$-2 |
| 2018-03-31 |
$-2 |
| 2017-12-31 |
$-3 |
| 2017-09-30 |
$-4 |
| 2017-06-30 |
$-3 |
| 2017-03-31 |
$-2 |
| 2016-12-31 |
$-2 |
| 2016-09-30 |
$-2 |
| 2016-06-30 |
$-3 |
| 2016-03-31 |
$-3 |
| 2015-12-31 |
$-3 |
| 2015-09-30 |
$-3 |
| 2015-06-30 |
$-3 |
| 2015-03-31 |
$-3 |
| 2014-12-31 |
$-3 |
| 2014-09-30 |
$-4 |
| 2014-06-30 |
$-3 |
| 2014-03-31 |
$-3 |
| 2013-12-31 |
$-2 |
| 2013-09-30 |
$-0 |
| 2013-06-30 |
$-0 |
| 2013-03-31 |
$-0 |
| 2012-12-31 |
|
| 2012-09-30 |
$-0 |
| 2012-06-30 |
|
| 2011-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.008B |
$0.005B |
|
Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California.
|
